Update re admission of Subscription Shares

RNS Number : 2255M

Advanced Oncotherapy PLC

20 September 2021

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Update re admission of Subscription Shares

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that further to its announcement of 3 September 2021, application has been made for the 82,383,761 Subscription Shares and 6,470,880 new ordinary shares in respect of the fee arrangements set out in the Company's announcement of 11 August 2021 to be admitted to trading on AIM ("First Admission").

First Admission will take place on or around 24 September 2021. The Company also announces that admission of the remaining 11,145,405 Subscription Shares will occur on or around 22 October 2021 ("Second Admission").

Upon First Admission, the Company's enlarged issued share capital will comprise 439,189,371 Ordinary Shares, with voting rights. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares in the Company with voting rights on First Admission will be 439,189,371. Upon Second Admission, the Company's enlarged issued share capital will comprise 450,334,776 Ordinary Shares, with voting rights. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares in the Company with voting rights on Second Admission will be 450,334,776. The aforementioned figures may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Defined terms used in this announcement shall have the same meaning as in the announcement of 11 August 2021 unless otherwise defined herein.

- ENDS -

Notes for editors

Advanced Oncotherapy plc	www.avoplc.com
Dr. Michael Sinclair, Executive Chairman	Tel: [phone]
Nicolas Serandour, CEO
Allenby Capital Limited  (Nomad and Joint Broker)
Nick Athanas / Liz Kirchner (Corporate Finance) Amrit Nahal / Matt Butlin (Sales and Corporate Broking)	Tel: [phone]
SI Capital Ltd  (Joint Broker)
Nick Emerson	Tel: [phone]
Jon Levinson	Tel: [phone]
FTI Consulting  (Financial PR & IR)	[e-mail]
Simon Conway / Rob Winder	Tel: [phone]

About Advanced Oncotherapy Plc

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END

 

 

MSCDKCBKFBKDPCD